Rena Conti

Minje, P., Carson, A., Erin, F., Conti, R. (In Press). “Stockpiling Medicines at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices”, Management Science

Park, M., Carson, A., Conti, R. (2025). “Linking Medication Errors to Drug Shortages: Evidence from Heparin Supply Chain Disruptions Caused by Hurricane Maria”, Manufacturing & Service Operations Management, 27 (4), 1008-1024

Conti, R., McCue, S., Dockter, T., Gunn, H., Dusetzina, S., Bennett, A., Rapkin, B., Gracia, G., Jazowski, S., Behrens, R., Richardson, P., Chow, S., Subbiah, N., Neuman, H., Chang, G., Weiss, E. (2025). “Observational survey of financial difficulties among patients with multiple myeloma and chronic lymphocytic leukaemia treated at US community oncology clinics (Alliance A231602CD).”, BMJ Open, 15 (6), e091769-

Conti, R., Demartino, P., Gruber, J., Lo, A., Sun, Y., Wu, J. (2025). “Innovative Insurance to Improve US Patient Access to Cell and Gene Therapy.”, Milbank Q, 103 (1), 32-51

Vogel, M., Tellier, A., Conti, R. (2024). “Predicting the next round of drugs for Medicare price negotiation.”, Sci Transl Med, 16 (776), eadq5711-

Conti, R., Mcglave, C., Rosenthal, M., Rodin, D. (2024). “US Trends In Anticancer Medicine Pricing And The Impact Of Competition, 2014-20.”, Health Aff (Millwood), 43 (12), 1719-1727

Kirchhoff, A., Waters, A., Liu, Q., Ji, X., Yasui, Y., Yabroff, K., Conti, R., Huang, I., Henderson, T., Leisenring, W., Armstrong, G., Nathan, P., Park, E. (2024). “Health insurance among survivors of childhood cancer following Affordable Care Act implementation.”, J Natl Cancer Inst, 116 (9), 1466-1478

Shapiro, G., Santiago, A., Pittman, T., Iwano, K., Rodin, G., Cole, H., Zeman, K., Sellmann, S., Oza, A., Jones, J., Rosenthal, M., Conti, R., Rodin, D. (2024). “Disparities in clinical trial enrollment at a Canadian comprehensive cancer center: A 15-year retrospective study.”, Cancer, 130 (16), 2782-2794

Levengood, T., Conti, R., Cahill, S., Cole, M. (2024). “Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.”, Milbank Q, 102 (2), 429-462

Wen, K., Harris, D., Chachlani, P., Hayes, K., McCarthy, E., Zullo, A., Smith-Ray, R., Singh, T., Djibo, D., McMahill-Walraven, C., Hiris, J., Conti, R., Gruber, J., Mor, V. (2024). “COVID-19 Vaccines: Moderna And Pfizer-BioNTech Use Varied By Urban, Rural Counties.”, Health Aff (Millwood), 43 (5), 659-665

Ohlsen, T., Wang, H., Buchbinder, D., Huang, I., Desai, A., Zheng, Z., Kirchhoff, A., Park, E., Krull, K., Conti, R., Yasui, Y., Leisenring, W., Armstrong, G., Yabroff, K., Nathan, P., Chow, E. (2024). “Financial hardship among siblings of long-term survivors of childhood cancer: A Childhood Cancer Survivor Study report.”, Cancer, 130 (7), 1125-1136

Chua, K., Volerman, A., Zhang, J., Hua, J., Conti, R. (2024). “Antidepressant Dispensing to US Adolescents and Young Adults: 2016-2022.”, Pediatrics, 153 (3)

Vogel, M., Kakani, P., Chandra, A., Conti, R. (2024). “Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.”, Nat Biotechnol, 42 (3), 406-412

Waters, A., Liu, Q., Ji, X., Yasui, Y., Yabroff, K., Conti, R., Henderson, T., Huang, I., Leisenring, W., Armstrong, G., Nathan, P., Park, E., Kirchhoff, A. (2024). “Job lock among survivors of childhood cancer and their spouses post Affordable Care Act implementation: A Childhood Cancer Survivor Study brief report.”, Pediatr Blood Cancer, 71 (2), e30790-

Wong, C., Li, D., Wang, N., Gruber, J., Lo, A., Conti, R. (2023). “The estimated annual financial impact of gene therapy in the United States.”, Gene Ther, 30 (10-11), 761-773

Ohlsen, T., Wang, H., Buchbinder, D., Huang, I., Desai, A., Zheng, Z., Kirchhoff, A., Park, E., Krull, K., Conti, R., Yasui, Y., Leisenring, W., Armstrong, G., Yabroff, R., Nathan, P., Chow, E. (2023). “Financial hardship among siblings of long-term survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS) report.”, Journal of Clinical Oncology, 41 (16_suppl), 10048-10048

Chua, K., Nguyen, T., Zhang, J., Conti, R., Lagisetty, P., Bohnert, A. (2023). “Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022.”, JAMA, 329 (16), 1402-1404

Hager, A., Gracia, G., Rodin, D., Conti, R. (2023). “Out-of-Pocket Costs of Treatment Among Employer-Insured Women With Invasive Breast Cancer.”, JAMA Netw Open, 6 (3), e231507-

Nathan, P., Huang, I., Chen, Y., Henderson, T., Park, E., Kirchhoff, A., Robison, L., Krull, K., Leisenring, W., Armstrong, G., Conti, R., Yasui, Y., Yabroff, K. (2023). “Financial Hardship in Adult Survivors of Childhood Cancer in the Era After Implementation of the Affordable Care Act: A Report From the Childhood Cancer Survivor Study.”, J Clin Oncol, 41 (5), 1000-1010

Becker, N., Seelye, S., Chua, K., Echevarria, K., Conti, R., Prescott, H. (2023). “Dispensing of Ivermectin From Veterans Administration Pharmacies During the COVID-19 Pandemic.”, JAMA Netw Open, 6 (2), e2254859-

Chua, K., Conti, R. (2023). “Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015-2019.”, J Gen Intern Med, 38 (2), 538-541

Akesson, J., Weiss, E., Sae-Hau, M., Gracia, G., Lee, M., Culp, L., Connell, B., Butterfield, S., Conti, R. (2023). “COVID-19 Vaccine-Related Beliefs and Behaviors Among Patients With and Survivors of Hematologic Malignancies.”, JCO Oncol Pract, 19 (2), e167-e175

Park, M., Carson, A., Conti, R. (2023). “Linking Medication Errors to Supply Chain Disruptions: Evidence from Heparin Shortages Caused by Hurricane Maria”, SSRN Electronic Journal

Auty, S., Griffith, K., Shafer, P., Gee, R., Conti, R. (2022). “Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States.”, J Health Polit Policy Law, 47 (6), 691-708

Frank, R., Conti, R., Gruber, J. (2022). “International Reference Pricing in the Context of US Drug Policy.”, J Health Polit Policy Law, 47 (6), 779-796

Levengood, T., Aronsohn, A., Chua, K., Conti, R. (2022). “Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data.”, Am J Prev Med, 63 (4), 532-542

Smith, G., Banegas, M., Acquati, C., Chang, S., Chino, F., Conti, R., Greenup, R., Kroll, J., Liang, M., Pisu, M., Primm, K., Roth, M., Shankaran, V., Yabroff, K. (2022). “Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.”, CA Cancer J Clin, 72 (5), 437-453

Corrigan, K., Fu, S., Chen, Y., Kaiser, K., Roth, M., Peterson, S., Shih, Y., Jagsi, R., Giordano, S., Volk, R., Yabroff, K., Banegas, M., Acquati, C., Conti, R., Ma, H., Ku, K., You, Y., Smith, G. (2022). “Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery.”, Cancer, 128 (13), 2455-2462

Rodin, D., Rosenthal, M., McGlave, C., Bhaskar, A., To, C., Conti, R. (2022). “National trends in post-launch cancer prescription drug prices and the impact of generic entry, 2014-2020.”, Journal of Clinical Oncology, 40 (16_suppl), 6598-6598

Mattingly, T., Conti, R. (2022). “Ensuring a high-quality and resilient supply chain of essential medications means paying more.”, J Manag Care Spec Pharm, 28 (5), 573-576

Volerman, A., Pelczar, A., Conti, R., Ciaccio, C., Chua, K. (2022). “Association between dispensing of low-value oral albuterol and removal from Medicaid preferred drug lists.”, BMC Health Serv Res, 22 (1), 562-

Chua, K., Dahlem, C., Nguyen, T., Brummett, C., Conti, R., Bohnert, A., Dora-Laskey, A., Kocher, K. (2022). “Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021.”, Ann Emerg Med, 79 (3), 225-236

Chua, K., Conti, R., Becker, N. (2022). “US Insurer Spending on Ivermectin Prescriptions for COVID-19.”, JAMA, 327 (6), 584-587

Chua, K., Conti, R., Becker, N. (2022). “Trends in and Factors Associated With Out-of-Pocket Spending for COVID-19 Hospitalizations From March 2020 to March 2021.”, JAMA Netw Open, 5 (2), e2148237-

Chua, K., Fendrick, A., Conti, R., Moniz, M. (2022). “Out-of-Pocket Spending for Deliveries and Newborn Hospitalizations Among the Privately Insured”, Obstetrical & Gynecological Survey, 77 (1), 11-13

Rodin, D., Rosenthal, M., McGlave, C., Bhaskar, A., To, C., Conti, R. (2022). “National trends in post-launch cancer prescription drug prices and the impact of generic entry, 2014-2020.”, JOURNAL OF CLINICAL ONCOLOGY, 40 (16)

Killelea, A., Johnson, J., Dangerfield, D., Beyrer, C., McGough, M., McIntyre, J., Gee, R., Ballreich, J., Conti, R., Horn, T., Pickett, J., Sharfstein, J. (2022). “Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic.”, J Law Med Ethics, 50 (S1), 8-23

Ballreich, J., Levengood, T., Conti, R. (2022). “Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV.”, J Law Med Ethics, 50 (S1), 32-39

Sharfstein, J., Conti, R., Gee, R. (2022). “From COVID Vaccines to HIV Prevention: Pharmaceutical Financing and Distribution for the Public’s Health.”, J Law Med Ethics, 50 (S1), 29-31

Conti, R., Frank, R., Nichols, L. (2021). “How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation?”, JAMA Health Forum, 2 (12), e214242-

Maldonado, J., Fu, S., Chen, Y., Acquati, C., Yabroff, K., Banegas, M., Chang, S., Conti, R., Checka, C., Peterson, S., Advani, P., Ku, K., Jagsi, R., Giordano, S., Volk, R., Shih, Y., Smith, G. (2021). “Sensitivity of Psychosocial Distress Screening to Identify Cancer Patients at Risk for Financial Hardship During Care Delivery.”, JCO Oncol Pract, 17 (12), e1856-e1865

Conti, R., Frank, R., Gruber, J. (2021). “Regulating Drug Prices while Increasing Innovation.”, N Engl J Med, 385 (21), 1921-1923

Chua, K., Conti, R. (2021). “Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications.”, JAMA Netw Open, 4 (11), e2134142-

Chua, K., Conti, R., Becker, N. (2021). “Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020.”, JAMA Netw Open, 4 (10), e2129894-

Chua, K., Brummett, C., Conti, R., Bohnert, A. (2021). “Opioid Prescribing to US Children and Young Adults in 2019.”, Pediatrics, 148 (3)

Chua, K., Volerman, A., Conti, R. (2021). “Prescription Drug Dispensing to US Children During the COVID-19 Pandemic.”, Pediatrics, 148 (2)

Mattingly, T., Seo, D., Ostrovsky, A., Vanness, D., Conti, R. (2021). “60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad.”, Res Social Adm Pharm, 17 (8), 1489-1495

Conti, R., Padula, W., Becker, R., Salamone, S. (2021). “The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia.”, J Manag Care Spec Pharm, 27 (8), 1077-1085

Chua, K., Fendrick, A., Conti, R., Moniz, M. (2021). “Prevalence and Magnitude of Potential Surprise Bills for Childbirth.”, JAMA Health Forum, 2 (7), e211460-

Chua, K., Fendrick, A., Conti, R., Moniz, M. (2021). “Out-of-Pocket Spending for Deliveries and Newborn Hospitalizations Among the Privately Insured.”, Pediatrics, 148 (1)

Conti, R., McCue, S., Dockter, T., Rapkin, B., Dusetzina, S., Bennett, A., Gracia, G., Johnson, M., Martin, S., Chang, G., Richardson, P., Behrens, R., Weiss, E. (2021). “Assessing financial difficulty in patients with multiple myeloma: Preliminary results of ALLIANCE A231602CD.”, Journal of Clinical Oncology, 39 (15_suppl), 8031-8031

Nathan, P., Huang, I., Chen, Y., Henderson, T., Park, E., Kirchhoff, A., Robison, L., Krull, K., Armstrong, G., Leisenring, W., Conti, R., Yasui, Y., Yabroff, R. (2021). “Financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).”, Journal of Clinical Oncology, 39 (15_suppl), 10026-10026

Conti, R., Lo, A., Wong, C., Gruber, J. (2021). “Estimating the Financial Impact of Gene Therapy in the U.S.”,

Chua, K., Conti, R. (2021). “Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage.”, Am J Prev Med, 60 (4), 537-541

Chua, K., Kimmel, L., Conti, R. (2021). “Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.”, Health Aff (Millwood), 40 (3), 453-460

Conti, R., Turner, A., Hughes-Cromwick, P. (2021). “Projections of US Prescription Drug Spending and Key Policy Implications.”, JAMA Health Forum, 2 (1), e201613-

Chua, K., Lee, J., Conti, R. (2021). “Potential Change in Insulin Out-of-Pocket Spending Under Cost-Sharing Caps Among Pediatric Patients With Type 1 Diabetes.”, JAMA Pediatr, 175 (1), 90-92

Padula, W., Parasrampuria, S., Socal, M., Conti, R., Anderson, G. (2020). “Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US”.”, Pharmacoeconomics, 38 (12), 1375-1376

Chua, K., Conti, R. (2020). “Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.”, JAMA Intern Med, 180 (10), 1273-1274

Padula, W., Parasrampuria, S., Socal, M., Conti, R., Anderson, G. (2020). “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.”, Pharmacoeconomics, 38 (10), 1115-1121

Chua, K., Conti, R. (2020). “Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013-18.”, Health Aff (Millwood), 39 (10), 1806-1811

Chua, K., Lee, J., Conti, R. (2020). “Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes.”, JAMA Intern Med, 180 (7), 1012-1014

Kimmel, L., Conti, R., Volerman, A., Chua, K. (2020). “Pediatric Orphan Drug Indications: 2010-2018.”, Pediatrics, 145 (4)

Nikpay, S., Buntin, M., Conti, R. (2020). “Relationship between initiation of 340B participation and hospital safety-net engagement.”, Health Serv Res, 55 (2), 157-169

Conti, R., Dusetzina, S., Sachs, R. (2020). “How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.”, Health Aff (Millwood), 39 (3), 445-452

Chua, K., Brummett, C., Conti, R., Bohnert, A. (2020). “Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults.”, JAMA Pediatr, 174 (2), 141-148

Chua, K., Schwartz, A., Volerman, A., Conti, R., Huang, E. (2020). “Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured Children.”, Pediatrics, 145 (2)

Vermeulen, L., Swarthout, M., Alexander, G., Ginsburg, D., Pritchett, K., White, S., Tryon, J., Emmerich, C., Nesbit, T., Greene, W., Fox, E., Conti, R., Scott, B., Sheehy, F., Melby, M., Lantzy, M., Hoffman, J., Knoer, S., Zellmer, W. (2020). “ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems.”, Am J Health Syst Pharm, 77 (2), 84-112

Conti, R., David, F. (2020). “Public research funding and pharmaceutical prices: do Americans pay twice for drugs?”, F1000Res, 9 707-

Fox, E., Conti, R. (2020). “Pharmacy Forecast 2020: Pharmaceutical Supply Chain”, AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 77 (2), 101-103

Woo, J., Anderson, B., Gruenstein, D., Conti, R., Chua, K. (2019). “Minimum Travel Distance Among Publicly Insured Infants with Severe Congenital Heart Disease: Potential Impact of In-state Restrictions.”, Pediatr Cardiol, 40 (8), 1599-1608

Chen, A., Hu, X., Conti, R., Jena, A., Goldman, D. (2019). “Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.”, Value Health, 22 (12), 1387-1395

Conti, R., Berndt, E., Shivdasani, Y., Kaygisiz, N. (2019). “The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications”,

Conti, R. (2019). “Financial Toxicity of Prescription Drugs.”, Ann Intern Med, 171 (9), 665-666

Conti, R., Berndt, E., Adajar, P. (2019). “The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration”,

Conti, R., Nikpay, S., Buntin, M. (2019). “Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016”, JAMA Network Open, 2 (10), e1914141-e1914141

Conti, R. (2019). “3 Things You Need to Know About Prescription Drug Affordability”, Institute for Health System Innovation & Policy

Conti, R. (2019). “The Orphan Drug Act: IHSIP Expertise in Policy Action”,

Conti, R., Berndt, E. (2019). “Four Facts Concerning Competition in US Generic Prescription Drug Markets”, International Journal of the Economics of Business 1-22

Conti, R., Berndt, E. (2019). “Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets”,

Conti, R., Kleutghen, P. (2019). “Is ‘Competitive Licensing’ Proposed In HR 1046 Practical For Lowering Drug Prices?”, Health Affairs

Conti, R., Chua, K. (2019). “Orphan Drugs For Opioid Use Disorder: An Abuse Of The Orphan Drug Act”, Health Affairs

Royce, T., Kircher, S., Conti, R. (2019). “Pharmacy Benefit Manager Reform”, JAMA, 322 (4), 299-299

Conti, R., David, F. (2019). “Rebalancing High Prescription Drug Prices With Innovation Incentives”, Health Affairs

Chua, K., Brummett, C., Conti, R., Haffajee, R., Prosser, L., Bohnert, A. (2019). “Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids”, JAMA Network Open, 2 (5), e193673-e193673

Chua, K., Conti, R. (2019). “Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014”, Journal of General Internal Medicine, 34 (3), 338-340

GaBI Journal Editor, . (2018). “US generic prescription drug markets 2004–2016”, Generics and Biosimilars Initiative Journal, 7 (4), 164-164

Parsons, S., Castellino, S., Rodday, A., Keller, F., Kelly, K., Conti, R., Lerner, D., Henderson, T. (2018). “Productivity Loss Among Parent Caregivers Is Associated with Poor Health-Related Quality of Life (HRQL) at the Intial Diagnosis of Pediatric Advanced Stage Hodgkin Lymphoma (HL)”, Blood, 132 (Supplement 1), 975-975

Conti, R., Nikpay, S., Buntin, M. (2018). “Diversity of Participants in the 340B Drug Pricing Program for US Hospitals”, Journal of the American Medical Association Internal Medicine, 178 (8), 1124-1127

Conti, R., Nguyen, K., Rosenthal, M. (2018). “Generic Prescription Drug Price Increases: Which Products Will Be Affected by Proposed Anti-Gouging Legislation”, Journal of Pharmaceutical Policy and Practice, 11 (1), 29-29

Conti, R., Chua, K. (2018). “Out-of-Pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014”, Journal of General Internal Medicine, 178 (4), 133-140

(2018). “AMCP Partnership Forum: Driving Value and Outcomes in Oncology.”, J Manag Care Spec Pharm, 24 (6), 572-578

Parsons, S., Lerner, D., Rodday, A., Curtis, R., Kelly, K., Conti, R., Castellino, S., Henderson, T. (2018). “Parental work limitations at diagnosis of advanced stage pediatric Hodgkin lymphoma—Results of caregiver work limitations questionnaire (CG WLQ).”, Journal of Clinical Oncology, 36 (15_suppl), e18927-e18927

Berndt, E., Conti, R., Murphy, S. (2018). “The generic drug user fee amendments: an economic perspective”, Journal of Law and the Biosciences, 5 (1), 103-141

Aggarwal, M., Devries, S., Freeman, A., Ostfeld, R., Gaggin, H., Taub, P., Rzeszut, A., Allen, K., Conti, R. (2018). “The Deficit of Nutrition Education of Physicians.”, Am J Med, 131 (4), 339-345

Conti, R., Berndt, E. (2018). Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007. In David, Cutler. (Eds.), “Measuring and Modeling Health Care Costs Advances in CRIW Conference Proceedings”, University of Chicago Press

Conti, R., Chua, K., Shrime, M. (2017). “Effect of FDA Investigation on Opioid Prescribing to Children after Tonsillectomy/Adenoidectomy”, Pediatrics, 140 (6), 6-6

Conti, R. (2017). “Making Medicines Affordable: A National Imperative — A Review”, Health Affairs

Conti, R., Nikpay, S., Buntin, M. (2017). “The 340B Program: Mandatory Reporting, Alternative Eligibility Criteria Should Be Top Priorities for Congress”, Health Affairs

Dusetzina, S., Conti, R., Yu, N., Bach, P. (2017). “Association of Prescription Drug Price Rebates in Medicare Part D with Patient Out-of-Pocket and Federal Spending”, Journal of the American Medical Association Internal Medicine, 177 (8), 1185-1188

Conti, R. (2017). “Biosimilars: Reimbursement Issues in Your Oncology Practice”, Journal of Oncology Practice, 13 (9), 12-14

Conti, R., DeSouza, J. (2017). “Mitigating Financial Toxicity among US Patients with Cancer”, Journal of the American Medical Association Oncology, 3 (6), 765-766

Conti, R. (2017). “Biosimilars: Reimbursement Issues in Your Oncology Practice.”, Journal of oncology practice, 13 (9_suppl), 12s-14s

Conti, R., Berndt, E. (2017). “The Generic Drug User Fee Amendments: An Economic Perspective”,

Conti, R., Murphy, S., Berndt, E. (2017). “The Landscape of US Generic Prescription Drug Markets, 2004–2016”, The National Bureau of Economic Research

Conti, R., Chua, K. (2017). “Out-of-Pocket Spending among Commercially Insured Patients for Epinephrine Autoinjectors between 2007 and 2014”, Journal of the American Medical Association Internal Medicine, 176 (2), 736-739

Chua, K., Conti, R. (2017). “Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014.”, JAMA Intern Med, 177 (5), 736-739

Conti, R., Jones, D. (2017). “Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA”, Journal of Health Politics, Policy and Law, 42 (2), 377-385

Chua, K., Conti, R., Freed, G. (2017). “Appropriately Framing Child Health Care Spending: A Prerequisite for Value Improvement”,

Conti, R., padula, w. (2017). Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the U.S. and the E.U.. In Richard, Hehlmann. (Eds.), “Chronic Myeloid Leukemia: What Every Clinical Practitioner Needs to Know in 2017”, ASCO

Dragoni, F., Conti, R., Cazzaniga, S., Colucci, R., Pisaneschi, L., Naldi, L., Moretti, S. (2017). “No Association between Vitiligo and Obesity: A Case-Control Study.”, Med Princ Pract, 26 (5), 421-426

Henderson, T., Castellino, S., Keller, F., Kelly, K., Curtis, R., Conti, R., Parsons, S. (2016). “Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents”, Blood, 128 (22), 3583-3583

Darlington, W., Watson, S., Henderson, T., Cunningham, J., Conti, R. (2016). “The Affordable Care Act Improves Healthcare Access and Utilization Among Young Adults with Sickle Cell Disease”, Blood, 128 (22), 4747-4747

Chua, K., Schwartz, A., Volerman, A., Conti, R., Huang, E. (2016). “Use of Low-Value Pediatric Services Among the Commercially Insured”, PEDIATRICS, 138 (6), e20161809-e20161809

Conti, R., Gee, R., Sharfstein, J. (2016). “Pharmaceuticals and Public Health.”, JAMA, 316 (20), 2083-2084

Pitts, P., Louet, H., Moride, Y., Conti, R. (2016). “21st century pharmacovigilance: efforts, roles, and responsibilities.”, Lancet Oncol, 17 (11), e486-e492

Conti, R. (2016). “The Advantages of Awarding the Federal Government Negotiating Power Over the Prices of Prescription Drugs”, Journal of Policy Analysis and Management, 35 (4), 964-970

Conti, R. (2016). “Response to Joyce and Sood”, Journal of Policy Analysis and Management, 35 (4), 972-974

Padula, W., Larson, R., Dusetzina, S., Apperley, J., Hehlmann, R., Baccarani, M., Eigendorff, E., Guilhot, J., Guilhot, F., Hehlmann, R., Mahon, F., Martinelli, G., Mayer, J., Müller, M., Niederwieser, D., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Conti, R. (2016). “Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.”, J Natl Cancer Inst, 108 (7)

Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2016). “A Pathway Through the Bundle Jungle.”, J Oncol Pract, 12 (6), 504-509

Weiner, A., Conti, R., Eggener, S. (2016). “National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions.”, J Urol, 195 (5), 1383-1389

Clark, B., Hou, J., Huang, E., Conti, R., Chou, C. (2016). “Medication Adherence among Hiv/Aids Patients Receiving 340b-Purchased Antiretroviral Medications”, Value in Health, 19 (3), A8-A8

Bach, P., Conti, R., Muller, R., Schnorr, G., Saltz, L. (2016). “Overspending driven by oversized single dose vials of cancer drugs.”, BMJ, 352 i788-

Conti, R., Rosenthal, M. (2016). “Pharmaceutical Policy Reform–Balancing Affordability with Incentives for Innovation.”, N Engl J Med, 374 (8), 703-706

Castellino, S., Henderson, T., Keller, F., Kelly, K., Curtis, R., Conti, R., Parsons, S. (2016). “APPROACH AND FEASIBILITY OF PATIENT-REPORTED OUTCOMES IN A PHASE III CLINICAL TRIAL FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN CHILDREN AND ADOLESCENTS”, HAEMATOLOGICA, 101 37-37

Dusetzina, S., Ellis, S., Freedman, R., Conti, R., Winn, A., Chambers, J., Alexander, G., Huskamp, H., Keating, N. (2015). “How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.”, J Oncol Pract, 11 (4), 313-318

Padula, W., Larson, R., Conti, R., Dusetzina, S. (2015). “Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis”, Value in Health, 18 (3), A205-A205

Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2015). “Reply to M. Thompson et Al.”, J Oncol Pract, 11 (3), 263-264

Conti, R., Padula, W., Larson, R. (2015). “Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.”, Ann Hematol, 94 Suppl 2 (0 2), S249-S257

Gibbons, R., Coca Perraillon, M., Hur, K., Conti, R., Valuck, R., Brent, D. (2015). “Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents.”, Pharmacoepidemiol Drug Saf, 24 (2), 208-214

Conti, R. (2015). “Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change.”, J Oncol Pract, 11 (1), e95-e97

Polite, B., Conti, R., Ward, J. (2015). “Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.”, Am Soc Clin Oncol Educ Book e75-e80

Howard, D., Bach, P., Berndt, E., Conti, R. (2015). “Pricing in the Market for Anticancer Drugs.”, J Econ Perspect, 29 (1), 139-162

Larson, R., Conti, R., Padula, W., Apperley, J., Baccarani, M., Eigendorff, E., Guilhot, F., Guilhot, J., Mahon, F., Martinelli, G., Mayer, J., Mueller, M., Niederwieser, D., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Hehlmann, R. (2014). “What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?”, Blood, 124 (21), 738-738

Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2014). “Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.”, J Oncol Pract, 10 (6), 357-362

Conti, R., Bach, P. (2014). “Improving outpatient oncology practice: several steps into a long journey.”, J Oncol Pract, 10 (6), 355-356

Clark, B., Hou, J., Chou, C., Huang, E., Conti, R. (2014). “The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.”, Health Aff (Millwood), 33 (11), 2012-2017

Padula, W., Conti, R., Larson, R. (2014). “What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?”, Value Health, 17 (7), A636-

Conti, R., Fein, A., Bhatta, S. (2014). “National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.”, Health Aff (Millwood), 33 (10), 1721-1727

Conti, R., Bach, P. (2014). “The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.”, Health Aff (Millwood), 33 (10), 1786-1792

Howard, D., Conti, R. (2014). “Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013.”, Journal of Clinical Oncology, 32 (15_suppl), 6525-6525

Goldberg, P., Conti, R. (2014). “Problems with public reporting of cancer quality outcomes data.”, J Oncol Pract, 10 (3), 215-218

Dusetzina, S., Winn, A., Chambers, J., Ellis, S., Conti, R., Freedman, R., Alexander, G., Keating, N., Huskamp, H. (2014). “Payer-Level Differences in the Response to Regulatory Actions Regarding Withdrawal of Breast Cancer as an Indication for Bevacizumab”, JOURNAL OF WOMENS HEALTH, 23 (10), 857-857

Conti, R. (2013). “Drug discount program–reply.”, JAMA, 310 (15), 1627-

Conti, R., Dusetzina, S., Herbert, A., Berndt, E., Huskamp, H., Keating, N. (2013). “The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.”, Med Care, 51 (7), 622-627

Conti, R., Bach, P. (2013). “Cost consequences of the 340B drug discount program.”, JAMA, 309 (19), 1995-1996

Kornfield, R., Watson, S., Higashi, A., Conti, R., Dusetzina, S., Garfield, C., Dorsey, E., Huskamp, H., Alexander, G. (2013). “Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.”, Psychiatr Serv, 64 (4), 339-346

Conti, R., Bernstein, A., Villaflor, V., Schilsky, R., Rosenthal, M., Bach, P. (2013). “Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.”, J Clin Oncol, 31 (9), 1134-1139

Bhatta, S., Fein, A., Conti, R. (2013). “TRENDS IN SPENDING ON ORAL CHEMOTHERAPEUTIC AGENTS 2006-2012”, CLINICAL PHARMACOLOGY & THERAPEUTICS, 93 S12-S12

Dusetzina, S., Busch, A., Conti, R., Donohue, J., Alexander, G., Huskamp, H. (2012). “Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory.”, Pharmacoepidemiol Drug Saf, 21 (12), 1251-1260

Dusetzina, S., Higashi, A., Dorsey, E., Conti, R., Huskamp, H., Zhu, S., Garfield, C., Alexander, G. (2012). “Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.”, Med Care, 50 (6), 466-478

Conti, R., Rosenthal, M., Polite, B., Bach, P., Shih, Y. (2012). “Infused chemotherapy use in the elderly after patent expiration.”, Am J Manag Care, 18 (5), e173-e178

Conti, R., Rosenthal, M., Polite, B., Bach, P., Shih, Y. (2012). “Infused chemotherapy use in the elderly after patent expiration.”, J Oncol Pract, 8 (3 Suppl), e18s-e23s

Philipson, T., Eber, M., Lakdawalla, D., Corral, M., Conti, R., Goldman, D. (2012). “An analysis of whether higher health care spending in the United States versus Europe is ‘worth it’ in the case of cancer.”, Health Aff (Millwood), 31 (4), 667-675

Pillarella, J., Higashi, A., Alexander, G., Conti, R. (2012). “Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009.”, Psychiatr Serv, 63 (1), 83-86

Garfield, C., Dorsey, E., Zhu, S., Huskamp, H., Conti, R., Dusetzina, S., Higashi, A., Perrin, J., Kornfield, R., Alexander, G. (2012). “Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.”, Acad Pediatr, 12 (2), 110-116

Conti, R., Bernstein, A., Meltzer, D. (2012). “How do initial signals of quality influence the diffusion of new medical products? The case of new cancer drug treatments.”, Adv Health Econ Health Serv Res, 23 123-148

Conti, R. (2011). “Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005”, Psychiatric Services, 62 (7), 720-720

Conti, R., Busch, A., Cutler, D. (2011). “Overuse of antidepressants in a nationally representative adult patient population in 2005.”, Psychiatr Serv, 62 (7), 720-726

Alexander, G., Garfield, C., Dorsey, R., Zhu, S., Higashi, A., Huskamp, H., Conti, R., Dusetzina, S. (2011). “US TRENDS IN THE DIAGNOSIS AND TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER, 2000-2010”, JOURNAL OF GENERAL INTERNAL MEDICINE, 26 S253-S253

Dusetzina, S., Alexander, G., Conti, R., Dorsey, E., Higashi, A., Zhu, S., Garfield, C., Huskamp, H. (2011). “Predictors of High Metabolic Risk Antipsychotic Use”, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 20 S264-S264

Garfield, C., Dorsey, E., Zhu, S., Higashi, A., Huskamp, H., Conti, R., Dusetzina, S., Alexander, G. (2011). “US Trends in the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, 2000-2010”, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 20 S197-S197

Qato, D., Lindau, S., Conti, R., Schumm, L., Alexander, G. (2010). “Racial and ethnic disparities in cardiovascular medication use among older adults in the United States.”, Pharmacoepidemiol Drug Saf, 19 (8), 834-842

Conti, R. (2010). “Advances in economics to further inform investments in vaccine development”, Human Vaccines, 6 (4), 286-291

Conti, R. (2010). “Advances in economics to further inform investments in vaccine development.”, Hum Vaccin, 6 (4), 289-291

Dorsey, E., Rabbani, A., Gallagher, S., Conti, R., Alexander, G. (2010). “Impact of FDA black box advisory on antipsychotic medication use.”, Arch Intern Med, 170 (1), 96-103

Conti, R., Veenstra, D., Armstrong, K., Lesko, L., Grosse, S. (2010). “Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.”, Med Decis Making, 30 (3), 328-340

Meltzer, D., Basu, A., Conti, R. (2010). “The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.”, Pharmacoeconomics, 28 (10), 843-853

Dorsey, R., Rabbani, A., Gallagher, S., Conti, R., Alexander, G. (2010). “IMPACT OF FDA BLACK BOX ADVISORY ON ANTIPSYCHOTIC MEDICATION USE”, JOURNAL OF INVESTIGATIVE MEDICINE, 58 (4), 675-675

Qato, D., Lindau, S., Conti, R., Alexander, G. (2009). “PIH51 Racial/Ethnic Disparities in Prescription Drug Use Among Older Adults in the United States”, Value in Health, 12 (3), A171-A171

Conti, R. (2009). “Value of research analysis: an application to drug development.”, Clin Adv Hematol Oncol, 7 (5), 298-300

Conti, R., Banks, J., Cornaglia, F. (2009). “LABOUR MARKET PARTICIPATION AND DEPRESSIVE SYMPTOMS AT OLDER AGES IN THE US AND UK”, GERONTOLOGIST, 49 19-19

Qato, D., Alexander, G., Conti, R., Johnson, M., Schumm, P., Lindau, S. (2008). “Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States.”, JAMA, 300 (24), 2867-2878

Conti, R., Meltzer, D., Ratain, M. (2008). “Nonprofit biomedical companies.”, Clin Pharmacol Ther, 84 (2), 194-197

Conti, R. (2008). “The societal benefit of nonprofit biotechnology companies.”, Clin Adv Hematol Oncol, 6 (5), 366-386

Rosenthal, M., Landrum, M., Meara, E., Huskamp, H., Conti, R., Keating, N. (2007). “Using performance data to identify preferred hospitals.”, Health Serv Res, 42 (6 Pt 1), 2109-2119

Chien, A., Conti, R., Pollack, H. (2007). “A pediatric-focused review of the performance incentive literature.”, Curr Opin Pediatr, 19 (6), 719-725

Frank, R., Conti, R., Goldman, H. (2005). “Mental Health Policy and Psychotropic Drugs”, The Milbank Quarterly, 83 (2), 271-298

Epstein, A., Ayanian, J., Keogh, J., Noonan, S., Armistead, N., Cleary, P., Weissman, J., David-Kasdan, J., Carlson, D., Fuller, J., Marsh, D., Conti, R. (2000). “Racial disparities in access to renal transplantation–clinically appropriate or due to underuse or overuse?”, N Engl J Med, 343 (21), 1537-1544

Conti, R., Neumann, P., Gruber, J., Ollandorf, D. (2000). “Valuing Rare Pediatric Drugs: An Economics Perspective”,